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Acute graft-versus-host disease (aGVHD) is a major cause of mortality in allogeneic bone marrow trans-
plantation. Here, the diminishing effect of activator protein 1 (AP-1) blocking with a synthetic retinoid
(SR11302) on the severity of aGVHD in a murine model was investigated. MHC-mismatched strain combi-
nations were used in vivo: C57BL/6 (H-2kb) donors into lethally irradiated BALB/c (H-2kd) recipients. SR11302
inhibited alloreactive T cell response in a dose-dependent manner and negatively regulated signal transducer
and activator of transcription 3 (STAT3) activation. AP-1 blocking in T cells inhibited the differentiation of Th1
and Th17. Conversely, Foxp3þ regulatory T cells (Treg) population dramatically expanded. Transfer of
SR11302-treated donor splenocytes into lethally irradiated recipients diminished the lethality and clinical
severity of aGVHD. In line with these results, AP-1 blocking in donor splenocytes exhibited reduced Th17/Th1
population and enhanced in vivo Treg population. Beneﬁcial Treg expanding property of SR11302 was
associated with the induction of Foxp3 and STAT5 transcription factor, where the inhibiting property of Th17
was achieved by suppressing the phosphorylated form of STAT3 and enhancing SOCS3. In conclusion, the
preventive potential of AP-1 inhibitor in aGVHD may be accomplished by altering CD4þ T cell differentiation
through modulating transcription factors.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative treatment for the life-threat-
ening hematological malignancies. However, acute graft-
versus-host disease (aGVHD) is the leading complication
of allogeneic HSCT and causes fatal morbidities [1]. The
improvements in conditioning regimens and infectious
prophylaxis have contributed to improved outcomes of
HSCT. However, aGVHD remains lethal and a signiﬁcant
obstacle. In fact, severe aGVHD occurs in approximately
50% of recipients who receive a human leukocyte anti-
genematched graft from an unrelated donor [2].
Graft-versus-host disease (GVHD) is a complex inﬂam-
matory process involving donor T cells that recognize MHC
on host-derived antigen-presenting cells (APCs) and dys-
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sues, such as the skin and gut, by donor T cells can lead to the
destruction of tissues [3]. Th1 cells and its associated cyto-
kine, interferon-g (IFN-g), have been reported to play a
critical role during aGVHD. However, recent research has
shown IL-17eproducing T (Th17) cell differentiation to affect
the progression of aGVHD. In vitro, polarized Th17 cells were
shown to induce lethal aGVHD [4]. On the opposite side of
Th17, there is a CD4þCD25þFoxp3þ regulatory T cells (Treg)
that plays a pivotal role for the maintenance of self-tolerance
in various autoimmune diseases and alloresponse [5-7].
Tregs contribute to the tolerance acquisition to donor antigen
in solid organ transplantations [8] and protect against the
development of fatal aGVHD in a murine model [9].
Despite clinical concerns, GVHD prophylaxis and treat-
ment rely heavily on unspeciﬁc immunosuppressive agents.
Prolonged immunosuppressive therapy increases the risk of
various complications, including severe infections, which
ultimately cause mortality in HSCT recipients. In addition,
immunosuppressive therapy has shown to reduce the effects
of T cellemediated graft-versus-leukemia (GVL) and subse-
quently increase the disease relapse rate.Transplantation.
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of a variety of dimers from the Fos and Jun families [10]. AP-1
is involved in cellular proliferation, death, survival, and dif-
ferentiation [11]. Although AP-1 is an important transcrip-
tion factor controlling the upregulation of proinﬂammatory
cytokines, its role in the pathogenesis of aGVHD remains
unknown. In the current study, the effects of SR11302 (an AP-
1 blocking synthetic retinoid), by inhibiting AP-1 activity, on
aGVHD severity and mortality have been investigated.
MATERIALS AND METHODS
Mice
Eight- to 10-week old C57BL/6 (H-2kb, termed B6) and BALB/c (H-2kd)
mice were purchased from OrientBio (Sungnam, Korea). Foxp3-GFP knock-
in mice (C57BL/6 strain) were purchased from the Jackson Laboratory (Bar
Harbor, ME). The mice were maintained under speciﬁc pathogen-free con-
ditions in an animal facility with controlled humidity (55%  5%), light (12/
12 hours light/dark), and temperature (22C  1C). The air in the facility
was passed through a high-efﬁciency particulate air ﬁlter system, designed
to exclude bacteria and viruses. Animals were fed mouse chow and tap
water ad libitum. The protocols used in this study were approved by the
Animal Care and Use Committee of The Catholic University of Korea.
Bone Marrow Transplantation Model and Histopathology Scoring
Recipients (BALB/c mice) were injected i.v. with 5  106 bone marrow
cells from donor mice after lethal irradiation with 800 cGy. To induce
aGVHD, splenocytes were isolated from B6. To depleted Treg cells of donor
cell, we added GFP-negative cells (non-Tregs) sorted from Foxp3-GFP mice
(B6 strain). The purity of the sorted CD4þFoxp3e cells was 98% to 99%, as
evaluated by ﬂow cytometry. B6 or sorted Foxp3 GFP-negative splenocytes
(1  107 cells) were incubated with 10 mM SR11302 or control (DMSO) for
2 hours at 37C before adoptive transfer into recipient mice. Survival after
bone marrow transplantation (BMT) was monitored daily, and the clinical
severity of aGVHD was assessed twice each week using a scoring system
evaluating changes in 5 clinical parameters: weight loss, posture, activity,
fur texture, and skin integrity [12]. Mice were sacriﬁced 14 days after BMT
for blinded histopathological analysis of GVHD targets (skin, liver, and small
and large intestine). Organs were harvested, cryo-embedded, and subse-
quently sectioned. Tissue sections were ﬁxed in 10% buffered formalin and
stained with H & E for histological examination.
Alloreactive T Cell Prolifereation In Vitro and Viability Studies
Splenic APC derived from B6 mice were used as allogeneic stimulators
and splenic T cells from BALB/c mice were used as responder cells in a mixed
lymphocyte reaction. T cell proliferation in this assay was used as a
parameter of alloreactivity. Red blood cells were removed, using an
ammonium-chloride-potassium lysis buffer; washed; and resuspended in
complete culture medium (RPMI 1640 medium supplemented with 10%
heat-inactivated fetal calf serum, 1mM sodium pyruvate, 5  105 M 2-ME,
20 mM HEPES, and antibiotics [100 U/mL penicillin, 100 mg/mL strepto-
mycin]). Aliquots of 2  105 CD4þ T cells (responder) were cultured with
2  105 irradiated (2500 cGy) APC in 96-well plates containing 200 mL of
complete medium at 37C in a humidiﬁed 5% CO2 atmosphere, pulsed with
1 mCi of [3H] TdR (NEN life Science Products Inc., Boston,MA) 18 hours before
harvesting, and counted using an automated harvester (PHD Cell Harvester;
Cambridge Technology, Inc., Cambridge, MA). Splenic T cells were cultured
with syngeneic splenic APC or allogeneic splenic APC in the absence or
presence of SR11302. Results are expressed as the mean counts per minute
(cpm) of triplicate samples standard deviation (SD). The stimulation index
was calculated by comparing the antistimulators response with the anti-
eself-response. The effect of SR11302 on the viability of cultured murine
splenocytes was determined using an MTT assay (Pierce, Rockford, IL).
Western Blot
Protein samples were separated by sodium dodecyl sulphate-poly-
acrylamide (SDS) gel electrophoresis and transferred to a nitrocellulose
membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). Mem-
braneswere stainedwith primary antibodies to c-Jun, c-Fos, phosphorylated
signal transducer and activator of transcription (STAT3) on tyrosine 705
(pSTAT3Tyr705) or on serine 727 (pSTAT3Ser727), STAT3 (all from Cell
Signaling, Danvers, MA), and b-actin. The HRP (Horseradish Peroxidase)-
conjugated secondary antibody was then added.
Flow Cytometry
Mononuclear cells were immunostained with various combinations of
the following ﬂuorescence-conjugated antibodies: CD4, CD25, Foxp3, IFN-g,IL-4, and IL-17. These cells were also intracellularly stained with the
following antibodies: IL-4 (BD Biosciences, San Jose, CA), IL-10 (Biolegend,
San Diego, CA), IL-17, and Foxp3 (eBioscience, San Diego, CA). Before intra-
cellular staining, the cells were restimulated for 4 hours with 25 ng/mL PMA
and 250 ng/mL ionomycin (Sigma, Saint Louis, MO) in the presence of
GolgiSTOP (BD Biosciences, San Jose, CA). Intracellular staining was con-
ducted using an intracellular staining kit (eBioscience) according to the
manufacturer’s protocol. Harvested cells were stained with surface mAb,
ﬁxed, permeabilized, and stained for anticytokine mAb. Flow cytometric
analysis was performed on a FACS Calibur cytometer (BD Biosciences).
Splenocytes isolated from B6mice were stimulated with (1 mg/mL) anti-CD3
mAb and (1 mg/mL) of anti-CD28 mAb (BD PharMingen, CA) for 72 hours.
Cells were stained ﬁrst with mAbs to CD4, CD25, inducible costimulator
(ICOS), glucocorticoid-induced TNF-related (GITR), and programmed death-
1 (PD-1), follow by mAbs to cytotoxic T lymphocyte antigen 4 (CTLA-4) and
Foxp3 using the regulatory T Cell Staining Kit (eBioscience). All analyses
were based on control cells incubated with appropriate isotype control to
adjust background ﬂuorescence.
Measurement of Cytokines
The concentrations of cytokines in culture supernatants were measured
using a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Duoset;
R&D Systems, Lille, France) as described by the manufacturer.
Reverse Transcriptionepolymerase Chain Reaction Analysis
Total RNA (2 mg) was reverse transcribed into cDNA using a transcription
kit (TaqMan Reverse Transcription Reagents; Applied Biosystems, Darm-
stadt, Germany). The resulting cDNA was ampliﬁed by PCR using Foxp3
sense (50- GGC CCT TCT CCA GGA CAG A-30) and antisense (50- GCT GAT CAT
GGC TGG GTT GT-30) primers and SOCS3 sense (50- CGC CTC AAG ACC TTC
AGC TC-30) and antisense (50- CTG ATC CAG GAA CTC CCG AA-30) primers.
PCR products were separated on a 1.5% agarose gel and stained with
ethidium bromide.
Confocal Staining
Spleen tissue was obtained 14 days after BMT and was snap-frozen in
liquid nitrogen and stored at 80C. Tissue cryosections (7 mm thick) were
ﬁxed with acetone and stained using PE-labeled anti-IFN-g, IL-4, IL-17, or
Foxp3 Ab (eBioscience), FITC-labeled anti-pSTAT3Tyr705, pSTAT3Ser727, pSTAT5,
PD-1, or GITR (eBioscience), PerCPelabeled anti-CD4 Ab (Biolegend), or APC-
labeled anti-CD25 Ab. In all experiments, background staining was estab-
lished using isotype-matched PE -, or FITC-conjugated isotype control. After
incubation overnight at 4C, stained sections were analyzed using a confocal
microscopy system (LSM 510 Meta. Zeiss, Gottingen, Germany).
Statistical Analysis
Data are presented as mean SD. Data comparisons betweenmore than
2 groups and between 2 groups were performed with Kruskal-Wallis test
and Mann-Whitney U-test or Student t test, respectively. To assess the
Gaussian distribution and the equality of variance, the Shapiro-Wilk test and
Leven test were used, respectively. The overall survival rate in aGVHD was
evaluated using the Kaplan-Meier estimate and compared using the log-
rank test. Weight data were analyzed at each time point. Statistical anal-
ysis was performed using the SPSS statistical software package (standard
version 16.0; SPSS, Chicago, IL). P values less than .05 (2-tailed) were
considered signiﬁcant.
RESULTS
AP-1Blocking Modulates Alloreactive T Cell Responses
In Vitro
Before the in vitro experiment, cell viability with
increasing treatment doses of SR11302 was assessed using
the MTT colorimetric assay. The results showed that SR11302
treatment up to 10 mM did not show any signiﬁcant toxicity
to murine splenocytes (Figure 1A). To determine the impact
of AP-1 activity on the proliferative capacity of donor CD4þ
T cells in response to alloantigens, T cell alloreactivity with
treatment of SR11302 was measured by incorporating [3H]-
thymidine. Proliferative responses to B6 splenic APC (allo-
geneic stimulator) were measured in BALB/c splenic T cells
(responder cells) and were compared with those of BALB/c
APC (syngeneic stimulator). BALB/c T cells that were incu-
bated with B6 splenic APC in the presence of SR11302 dis-
played decreased alloreactivity when compared with those
in the absence of SR11302 in a dose-dependent manner
Figure 1. SR11302 inhibits alloreactive T cell proliferation in vitro through downregulation of AP-1/STAT3 signaling. (A) The cellular viability to SR11302 treatment in
alloresponse condition in vitro was determined by MTT assay. A total of 2  105 RBC-lysed BALB/c splenic T cells (responders) were incubated with 2  105 irradiated
RBC-lysed BALB/c splenic APC (syngeneic stimulator) or C57BL/6 splenic APC (allogeneic stimulator) for 4 days. (B) In a mixed lymphocyte reaction assay, a total of
2  105 RBC-lysed BALB/c splenic T cells (responders) were incubated with 2  105 irradiated RBC-lysed BALB/c splenic APC (syngeneic stimulator) or C57BL/6 (B6)
splenic APC (allogeneic stimulator) for 4 days. Responder cells were cultured in the absence or presence of SR11302 (2.5 mM and 10 mM). SR11302 was added on day 0,
and T cell proliferation was measured by [3H]-thymidine incorporation in each group. (C) The supernatants were collected, and ELISAwas performed to determine the
IFN-g, IL-17, and IL-10 levels. Data represent means  SD of triplicates (*P < .05 versus alloresponse). (D) A total of 105 RBC-lysed BALB/c splenic T cells (responders)
were incubated with 105 irradiated RBC-lysed BALB/c splenic APC (syngeneic stimulator) or B6 splenic APC (allogeneic stimulators). SR11302 (2.5 mM) was added on
day 0 and cells were harvested on day 2. Then, western blotting analysis of AP-1 (D) and STAT3 phosphorylation associated protein expression (E) was performed in
each sample. (1: syngeneic stimulator, 2: allogeneic stimulator in the absence of SR11302, 3: allogeneic stimulator in the presence of SR11302).
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culture supernatants weremeasured using ELISA (Figure 1C).
Treatment with SR11302 markedly reduced IFN-g and IL-17
levels and reciprocally increased the level of IL-10 in a
dose-dependent manner (Figure 1D). To determine if the
inhibition effect of the AP-1 activity was due to the treatment
of SR11302, AP-1 proteins, c-Jun and c-Fos, were analyzed
using western blot. c-Jun and c-Fos expression were effec-
tively diminished with SR11302 treatment (Figure 1D). Total
STAT3 and pSTAT3 expressions were analyzed to examine if
SR11302 negatively regulates STAT3 activation in alloreactive
T cells (Figure 1E). STAT3 and pSTAT3 (pSTAT3Tyr705 and
pSTAT3Ser727) activity decreased after SR11302 treatment,
although the changes of pSTAT3 expressions were more
signiﬁcant than that of total STAT3 activity.
Altered Differentiation of T Cells In Vitro by AP-1
Blocking
IL-17eproducing cells (mainly Th17) and IFN-geproducing
cells (mainly Th1) increased in responder T cells stimulated
with allogeneic APC for 4 days (Figure 2A). Th17 and Th1 cells
decreased with SR11302 treatment in a dose-dependent
manner. Conversely, SR11302 increased approximately 2-fold
in CD4þFoxpþ Treg cells (Figure 2A). BALB/c splenic T cells
were incubated with anti-CD3 and anti-CD28 for 72 hours in
the presence or absence of SR11302 (10 mM). CD25þFoxp3þ-
double positive T cells dramatically increased (Figure 2B). The
suppressive function of Treg on conventional T cells wasgained through a cell-cell contact-dependent mechanism,
such as CTLA-4 [13]. The proportion of CTLA-4, ICOS, PD-1, or
GITR-expressing Treg were analyzed using ﬂow cytometry.
The CTLA-4 and ICOS-positive Treg populationwere increased
by SR11302 compared with control (Figure 2C). In conclusion,
AP-1 signaling blocking led to the attenuation of the allor-
eactive T cell response and Th17 differentiation via the inter-
ruption of STAT3 activity. Furthermore, results demonstrated
treatment with SR11302 in vitro can expand Treg and upre-
gulate CTLA-4 and ICOS molecules, thus showing enhanced
suppressor activity of Treg cells.
AP-1 Signaling Is Involved in aGVHD-induced Lethality
and Target Organ Damage
A T celledepleted BMT model was used as a negative
control. All of the control mice died from aGVHD, whereas
recipients of SR11302-treated splenocytes survived longer:
50% survived more than 60 days after BMT (Figure 3A).
Weight loss was fairly mitigated in SR11302-treated
aGVHD animals. SR11302-treated aGVHD animals showed
less severe clinical scores compared with the control group
(Figure 3A). Skin, liver, and intestine are primary target
sites of aGVHD. Histopathology results on day 14 after
GVHD induction demonstrated signiﬁcantly improved
pathologic cutaneous lesions in SR11302-treated re-
cipients. Inﬂammatory cell inﬁltration and structural
destruction of intestinal mucosa that were shown in con-
trol recipients were also attenuated in SR11302-treated
Figure 2. Altered T cell differentiation after SR11302 treatment in donor allogeneic T cells is associated with reduced alloreactivity. (A) A total of 105 RBC-lysed BALB/c
splenic T cells (responders) were incubated with 105 irradiated RBC-lysed BALB/c splenic APC (syngeneic stimulator) or C57BL/6 splenic APC (allogeneic stimulator)
for 4 days. Responder cells were cultured in the absence or presence of SR11302 (2.5 mM and 10 mM). SR11302 was added on day 0 and cells were harvested on day 4.
Then, intracellular staining for IFN-g, IL-17, and Foxp3 in isolated CD4þ T cells was performed and analyzed by ﬂow cytometric analysis. Right panel shows the
absolute number of CD4þIFN-gþ, CD4þIL-17þ, CD4þCD25þFoxp3þ T cells. (B) Splenic T cells were incubated for 72 hours with plate-bound anti-CD3 (1 mg/mL) and
anti-CD28 (1 mg/mL) antibody in the absence or presence of 10 mM SR11302. CD4þCD25þFoxp3þ Treg cell proportion was analyzed by ﬂow cytometry. The data are
expressed as the mean  SD from 4 independent experiments. (C) The mean ﬂuorescence intensity (MFI) of various Treg markers, including CTLA-4, ICOS, PD-1, and
GITR, were analyzed by ﬂow cytometry. The data are expressed as mean  SD for 4 mice per group. *P < .05, **P < .01, and ***P < .001, compared with the vehicle
(control)-treated alloresponse.
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whether the protective function of SR11302 worked by
inhibiting the function of AP-1, the expression of its com-
ponents, c-Fos and c-Jun, in target organs were assessed by
confocal and immunohistochemical staining. The expres-
sion of both proteins in spleen, liver, and epithelial tissues
of the small intestine was signiﬁcantly reduced in
SR11302-treated aGVHD animals (Figure 3C,D).
The Preventive Effect of SR11302 Was Accompanied by
Altered T Cell Population In Vivo
The IFN-geproducing CD4þ cell population (mainly Th1)
and IL-17eproducing CD4þ T cells (mainly Th17) were
dramatically reduced in SR11302-treated GHVD recipients
(Figure 4A). Interestingly, IL-4eexpressing CD4þ T cells
(mainly Th2) slightly expanded, suggesting the differenti-
ation toward Th2 subtype after SR11302 treatment. SOCS3
has been shown to inhibit STAT4 signaling, leading the
immune response to skew toward Th2 [14]. Regarding the
fate of Th17, SOCS3 blocked STAT3 signaling, inhibiting the
generation of the Th17 population [15]. Foxp3 is essential
for differentiation of Treg cells [16]. Splenocytes isolatedfrom aGVHD mice that were transferred to SR11302-treated
splenocytes showed enhanced mRNA expression of SOCS3
and Foxp3 compared with the control group, suggesting the
mechanisms of the aGVHD attenuation by SR11302
(Figure 4B). In line with this, spleens isolated on day 14 after
BMT demonstrated that Th1 and Th17 dramatically
decreased in SR11302-treated recipients compared to the
vehicle-treated animals. Conversely, IL-4þCD4þ (mainly
Th2) and Foxp3þ CD4þ T (mainly Treg) cells were signiﬁ-
cantly enhanced in SR11302-treated GVHDmice (Figure 4C).
Those results suggest that AP-1 blocking in donor spleno-
cytes effectively attenuates aGVHD severity by altering the
differentiation of CD4þ T cells during the alloreactive T cell
responses.
Regulation of STAT3 and STAT5 Activity via AP-1 Signal
Blocking In Vivo
The expression of pSTAT3Tyr705 and pSTAT3Ser727 in
spleens isolated from aGVHD-receiving SR11302-treated
splenocytes displayed reduced pSTAT3 among CD4þ T cells.
Conversely, the expression of pSTAT5 demonstrated in
spleen dramatically increased in SR11302-treated mice
Figure 3. SR11302 suppresses the development of acute GVHD via blocking of c-Fos/c-Jun signaling. (A) C57BL/6 (B6) splenocytes (1 107 cells) were incubated with
10 mM of SR11302 or DMSO (control) for 2 hours at 37C before adoptive transfer into lethally irradiated (800 cGy) BALB/c (recipient) mice. Recipients also received
5  106 bone marrow cells from B6 mice and were monitored for weight loss, survival, and clinical scores of aGVHD. Lethal aGVHD shown in BALB/c recipients was
inhibited after administration of donor B6 splenocytes treated with SR11302. Recipient mice receiving T celledepleted bone marrow cells showed no signs of GVHD.
Data combined from 3 independent experiments (n ¼ 15 per group) are shown. (B) Histopathology of skin, small, and large intestine after BMT (n ¼ 6 per group),
which is representative of 2 independent experiments. Tissues isolated on day 14 after BMT were stained with H & E (original magniﬁcation, 200 ) (left panel) and
histological scores of each organ were higher in vehicle-treated animals, compared with those of SR11302etreated group (right pane). The data are expressed as the
mean  SD from 3 independent experiments for 5 mice per group. *P < .05, ***P < .001, compared with the vehicle-treated GVHD group. (C) Fourteen days after BMT,
splenocytes isolated from each group were stained with DAPI and anti-c-Fos or c-Jun antibodies, components of AP-1, and visualized by confocal microscopy.
Representative examples of confocal staining for c-Fos and c-Jun in spleen from GVHD mice. (D) Representative examples of immunohistochemical staining for c-Fos
and c-Jun, components of AP-1, in liver and small intestine tissue from GVHD mice. Positive immunoreactivity appears as a brown color and is counterstained with
blue (original magniﬁcation, 400 ).
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sive property of Treg, GITR and PD-1-expressing Treg por-
tions in the SR11302-treated group seemed to increase when
compared with the control group (Figure 5B). Thus, AP-1
signal blocking by SR11302 could prevent lethal aGVHD by
inhibiting STAT3 biologic activity and reciprocal induction of
STAT5.The Substantial Potential of Treg Cells to Attenuate the
Severity of aGVHD
As shown in Figure 6A, treatment with SR11302 on Treg
celledepleted donor splenocytes did not exert a signiﬁcant
beneﬁt on weight loss and survival gain. All recipient mice
failed to survive beyond 20 days after BMT. The ex vivo
results demonstrated that SR11302 treatment on Treg
Figure 4. Analysis of CD4þ T helper cells in SR11302-treated GVHD mice. (A) C57BL/6 (B6) splenocytes (1 107 cells) were incubated with SR11302 (10 mM) or vehicle
(DMSO) for 2 hours at 37C before adoptive transfer into lethally irradiated (800 cGy) BALB/c mice. Recipient BALB/c mice also received 5  106 bone marrow cells
from B6 mice. Intracellular cytokines were determined in the CD4þ T cells. Splenocytes of each group and were analyzed by ﬂow cytometry on day 14 after BMT.
Results are shown as mean  SD (n ¼ 5 per group). *P < .05, compared with the vehicle-treated GVHD group. (B) Fourteen days after BMT, the expression of Foxp3 and
SOCS3 mRNA was determined by RT-PCR analysis from whole splenocytes isolated from each group. (C) Spleens isolated on day 14 after BMT in each group were
analyzed by confocal microscopy for the expression of IFN-g, IL-4, IL-17, and Foxp3 among CD4þ cells. The proportions of IFN-g, IL-4, IL-17, or Foxp3 expressing CD4þ
cells in spleen were represented by bar graph (right panel) (mean  SD). The experiment was performed once with 6 mice per group. *P < .05, compared with the
vehicle-treated GVHD group.
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ferentiation of CD4þ T cells in recipient mice (Figure 6B).
Taken together, donor Treg cells may exert substantial direct
effects on the attenuated severity of aGVHD after SR11302
treatment.
DISCUSSION
We demonstrated that SR11302, an AP-1 inhibition-spe-
ciﬁc synthetic retinoid, can inhibit the expansion of Th1/Th17
through attenuation of STAT3 activity and SOCS3 induction.
In addition, SR11302 can induce Treg by enhanced phos-
phorylation of STAT5. Ultimately, AP-1 blocking in donor
lymphocytes led to reduced mortality in aGVHD recipients
and attenuated the clinical severity of aGVHD.
Although a recent study suggested that GVHD can be
elicited in the absence of host APCs [17], progression of
aGVHD is traditionally summarized in 3 sequential phases:
(1) activation of host APCs by the intensive conditioning
regimen, (2) activation and proliferation of alloreactive
donor T cells, and (3) subsequent tissue destruction [1].
Activated donor CD4þ T cells that interact with host APCs can
proliferate and differentiate into several types of Th cells:
Th1, Th2 and Th17 cells, depending on the milieu. aGVHD hasbeen traditionally proposed to be Th1-dominant condition.
But, donor cells isolated from mice lacking IFN-g, a key
cytokine of Th1, led to accelerated mortality due to aGVHD
[18]. Recently, Th17 cells have been reported to play a pivotal
role in some autoimmune diseases, including rheumatoid
arthritis [19] and autoimmune uveitis [20]. Yi et al. showed
that Th1 and Th17 cells play a different role under the pro-
gression of GVHD [21]. In their study, gut GVHD heavily de-
pends on Th1, whereas skin GVHD is Th17 dominant and lung
GVHD is Th2 dependent. On the opposing side of Th1 and
Th17, Treg plays a pivotal role in maintaining tolerance to
alloantigens, where Foxp3 was discovered to be a key tran-
scription factor, contributing new insights into Treg biology.
Regarding Treg induction, STAT5 has been considered to have
nonredundant roles. STAT5 can upregulate Foxp3 expression
by directly binding to the Foxp3 gene [22]. Removal of Treg
from the graft can accelerate aGVHD-induced mortality in
animal models [9,23]. However, Foxp3þ Treg cells can lose
Foxp3 expression in vivo and take on an effector memory
T cell phenotype [24,25]. Activated Treg cells with low
expression of Foxp3 have been described to produce more IL-
17 than any other CD4þ T cell fraction [26]. The plasticity of
Treg, as well as the scarcity of the circulating Treg population,
Figure 5. SR11302 regulate signaling of STAT3 and STAT5. (A) C57BL/6 (B6) splenocytes (1  107 cells) were incubated with SR11302 (10 mM) or vehicle (DMSO) for
2 hours at 37C before adoptive transfer into lethally irradiated (800 cGy) BALB/c mice. Recipient BALB/c mice also received 5  106 bone marrow cells from B6 mice.
The signal transducers STAT3 and STAT5 in the spleens were analyzed by confocal microscopy on day 14 after BMT in each group. Data are representative of 3
independent experiments. (B) Fourteen days after BMT, isolated spleens from each group were analyzed by confocal microscopy for the expression of GITR and PD-1
among CD4þCD25þFoxp3þ regulatory T cells. The experiment was performed once with 6 mice per group. Bars represent the mean  SD of 6 mice per group.
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immune diseases, including GVHD. However, preclinical ex-
periments have documented the preventive effect of Treg
[27] and GVHD-inducing effect of Th17 cells [4], which give
rise for the need of novel strategies that can induce Treg and
inhibit the differentiation and proliferation of Th1/Th17
lineages.
The prevention of aGVHD could be achieved by the
depletion or functional inactivation of donor immune cells
within the context of disease pathophysiology [28]. However,Figure 6. SR11302 plays a critical role in Tregs-mediated inhibition of aGVHD severi
with 10 mM of SR11302 or DMSO (control) for 2 hours at 37C before adoptive tran
received 5  106 bone marrow cells from B6 mice and were monitored for weight loss
intracellular staining for IFN-g, IL-17, CD25, and Foxp3 in isolated CD4þ T cells was pthat approach could be a double-edged sword because of the
reduced T celleinduced GVL effect in recipients. Treg cells
protect the host from autoimmune diseases by suppressing
self-reactive cells, blocking antitumor immune responses.
Furthermore, Treg cells found in solid cancers, such as lung
and ovarian cancer, were shown to secrete TGF-b, contrib-
uting to immune dysfunction in patients with cancer [29].
Curiel et al. demonstrated that Treg cells in ovarian cancer
may lead to the failure of host antitumor immunity, therefore
favoring tumor development or growth and inﬂuencing poorty. (A) Treg-depleted splenocytes (1  107 cells) from B6 mice were incubated
sfer into lethally irradiated (800 cGy) BALB/c (recipient) mice. Recipients also
and survival. (B) Spleens were isolated on day 10 after BMT in each group. Then,
erformed and analyzed by ﬂow cytometric analysis.
M.-J. Park et al. / Biol Blood Marrow Transplant 20 (2014) 1112e1120 1119survival [30]. However, it has not yet been discovered
whether elimination of Treg cells in hematologic malig-
nancies also exhibits antitumor immunity. A growing num-
ber of studies have suggested that Treg cells can reduce the
clinical severity of GVHD after allogeneic BMT in animal
models as well as in humans [31-33]. One decade ago,
Edinger et al. reported that Treg cells could be the potent
immunoregulatory T cells that inhibit lethal aGVHD while
preserving GVL effect in a murine model [34]. Furthermore, a
recent study demonstrated that adoptive transfer of Treg
leads to the preservation of thymic and peripheral lymph
node architecture as well as abrogation of GVHD [35]. Based
on these ﬁndings, expanding Treg population is a rational
therapeutic strategy to reduce the clinical severity of aGVHD
while preserving the GVT effects induced by conventional
T cells after allogeneic BMT. Therefore, the reciprocal regu-
lation of Th1/Th17 and Treg seems to be a rational approach
to inhibit fatal aGVHD as well as preserve the GVL effect to
prevent disease relapse. However, the probability that
enhanced Treg and inhibited Th17 populations in BMT re-
cipients could lead to attenuated GVL effects should be
addressed. Our study did not investigate whether SR11302
treatment affected the GVL effect or other immune function
in BMT recipients.
STAT3 has been revealed to be activated via tyrosine
phosphorylation of Tyr705 in response to various factors
such as IL-6 [36]. Despite of the dominant role of Tyr705
phosphorylation in STAT3 activation, Ser727 phosphory-
lationwas reported to be involved in maximal activity [37].
However, Ser727 phosphorylation could suppress STAT3
activity in another circumstance [38]. Despite the elusive
role of Ser727 in STAT3, we showed that the inhibitory
effects of SR11301 in an aGVHD model were associated
with decreased phosphorylation of both Ser727 and
Tyr705.
In conclusion, the present study demonstrated that AP-1
blocking in donor lymphocytes ameliorated lethal aGVHD
through the expansion of the Treg population as well as the
inhibition of Th17 differentiation and proliferation. AP-1
blocking in transplanted donor T cells seems to be a
reasonable strategy to prevent mortality and decrease the
severity of aGVHD in allogeneic HSCT recipients.
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